Core Scientific, Inc./tx
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
4 — Balance Sheet Components
- BALANCE SHEET COMPONENTS
Customer funding receivable and other current assets as of June 30, 2025 and December 31, 2024 consisted of the following (in thousands):
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Customer funding receivable | $230,672 | $7,442 |
| Other | 19,971 | 35,647 |
| Total customer funding receivable and other current assets | $250,643 | $43,089 |
Customer funding receivable represents amounts due from our customer for construction related payables and accrued expenses incurred on their behalf. The Company collects these amounts from the customer prior to payment to vendors. As of June 30, 2025, approximately $150.1 million of the related obligations were included in accounts payable and approximately $80.6 million were included in accrued expenses.
Accrued expenses as of June 30, 2025 and December 31, 2024 consisted of the following (in thousands):
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| Accrued customer funded construction | $80,618 | $— |
| Accrued capital expenditures | 67,643 | 12,106 |
| Other | 32,380 | 52,564 |
| Total accrued expenses | $180,641 | $64,670 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.